What is HC Wainwright’s Estimate for PepGen FY2025 Earnings?

PepGen Inc. (NASDAQ:PEPG) – Analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of PepGen in a report released on Thursday, January 30th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($2.42) per share for the year, up from their previous estimate of ($2.84). HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.73) per share. HC Wainwright also issued estimates for PepGen’s FY2026 earnings at ($2.08) EPS, FY2027 earnings at ($1.61) EPS and FY2028 earnings at ($1.01) EPS.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.21.

Several other brokerages also recently issued reports on PEPG. Wedbush cut their price target on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research report on Monday, December 16th.

PepGen Stock Down 10.4 %

Shares of NASDAQ PEPG opened at $1.29 on Monday. The firm’s 50-day moving average price is $3.76 and its two-hundred day moving average price is $7.25. PepGen has a 52-week low of $1.28 and a 52-week high of $19.30. The stock has a market capitalization of $42.05 million, a P/E ratio of -0.43 and a beta of 1.66.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC boosted its stake in PepGen by 331.2% during the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after purchasing an additional 1,794,641 shares in the last quarter. Suvretta Capital Management LLC raised its position in PepGen by 9.2% in the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after acquiring an additional 140,000 shares in the last quarter. Walleye Capital LLC acquired a new stake in PepGen in the 3rd quarter valued at about $519,000. Wellington Management Group LLP grew its stake in shares of PepGen by 76.9% in the 3rd quarter. Wellington Management Group LLP now owns 40,517 shares of the company’s stock worth $346,000 after purchasing an additional 17,618 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in shares of PepGen by 29.1% in the 3rd quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock worth $237,000 after purchasing an additional 6,254 shares in the last quarter. Institutional investors own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.